Clinigen
Clinigen is recorded as a service provider in 97 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 97 trials · Latest update first
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
Sponsor Janssen - Cilag International
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- Approximately 50% of the first 22 Part 1 participants experienced on-treatment ALT elevations, and protocol management criteria were amended because some elevations were prolonged.
- New enrollment was temporarily halted in December 2022 after significant ALT elevations were observed more frequently in Part 2 participants with screening or baseline HBsAg >10,000 IU/mL.
- Enrollment was not reopened because the sponsor discontinued further investment in its hepatitis B and D discovery and development programs.
- Part 2 open-label treatment was reduced to Week 96 and follow-up to 24 weeks under protocol amendment 5.
- Sustained HBV response was not collected or analyzed because follow-up was shortened and participants continued NA treatment during follow-up.
These findings describe the trial, not the service provider’s performance or responsibility.
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
Sponsor VarmX B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)
Sponsor Citryll B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis
Sponsor Biodexa Limited
- Start (EU)
- Latest update
- Estimated end
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA
Sponsor GBG Forschungs GmbH
- Start (EU)
- Latest update
- Estimated end
A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients undergoing complex cardiac surgery (involving CPB)
Sponsor LFB-Biotechnologies
- Start (EU)
- Latest update
- Estimated end
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
Sponsor Imcheck Therapeutics
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 44 participants at five centers in France, Germany, and the United Kingdom.
- Protocol amendments modified inclusion criteria and added or clarified exclusion criteria.
- Protocol amendments increased the Part 1 sample size, added and omitted dose-escalation cohorts, and added pembrolizumab as study treatment.
These findings describe the trial, not the service provider’s performance or responsibility.
HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability, and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/refractory cancer (EVICTION Study)
Sponsor Imcheck Therapeutics
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients
Sponsor Satellos Bioscience Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
Sponsor Agomab Spain S.L.U.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Efficacy and Tolerability of Fixed Duration Teclistamab and Talquetamab for Frail Patients with Newly Diagnosed Multiple Myeloma (2 Cohort Study) - the EMN 37 FITFIX FOR FRAIL Trial
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
Sponsor Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
- Start (EU)
- Latest update
- Estimated end
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-1)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
ETOP 18-21 AMAZE-lung: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
LIDRISE Study: A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
Sponsor Santen
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Clinigen?
The 2026-10-09 snapshot links Clinigen to 97 distinct CTIS trials. Recorded services include Medicinal product management, IMP importation, IMP Storage, distribution and destruction., Laboratory services, among 49 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Clinigen?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Haematological Malignancies, Blood Disorders, Gastroenterology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Clinigen conducted?
The linked trials record locations in 25 countries, including Spain, Germany, Italy, France, Netherlands. These are trial locations, not confirmed office locations or countries where Clinigen delivered services.
What can this page tell me about Clinigen's trial experience?
Browse 97 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 4 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 4 recorded name variants under Clinigen. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Clinigen Clinical Supplies Management
- Clinigen Clinical Supplies Management GmbH
- Clinigen Cts Limited
- Clinigen Healthcare Limited